Clinical and pharmacological properties of incobotulinumtoxina and its use in neurological disorders

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1913-1926

  Jost, Wolfgang H ^a   Benecke, Reiner ^b   Hauschke, Dieter ^a   Jankovic, Joseph ^c   Kaňovský, Petr ^d   Roggenkämper, Peter ^e   Simpson, David M ^f   Comella, Cynthia L ^g  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blepharospasm; Botulinum toxin; Cervical dystonia; IncobotulinumtoxinA; Spasticity; Xeomin

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY; PLACEBO;

BLEPHAROSPASM; CANCER PAIN; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; CERVICAL DYSTONIA; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSESTHESIA; DYSPHAGIA; ENTROPION; ESSENTIAL TREMOR; HEADACHE; HEMATOMA; HUMAN; HYPERSALIVATION; HYPESTHESIA; INDIVIDUALIZATION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INTELLECTUAL IMPAIRMENT; KERATITIS; LAGOPHTHALMOS; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUSICIAN'S DYSTONIA; NECK PAIN; NEUROLOGIC DISEASE; OPEN STUDY; PARKINSON DISEASE; PARKINSONISM; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLANTAR FASCIITIS; PROSPECTIVE STUDY; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; ROSACEA; SPASTICITY; NERVOUS SYSTEM DISEASES;

BOTULINUM TOXINS, TYPE A; HUMANS; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929174128     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79193     Document Type: Review

References (40)

1. Xeomin® (incobotulinumtoxinA) for injection, for intramuscular use [prescribing information]. Greensboro, NC: Merz Pharmaceuticals, LLC.; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125360s045lbl.pdf. Accessed December 16, 2014.
2. Merz Pharma UK Ltd. XEOMIN® 100 Units Summary of Product Characteristics [webpage on the Internet]. Electronic Medicine Compendium; 2014 [updated June 30, 2014]. Available from: http://www.medicines.org.uk/emc/medicine/20666. Accessed December 16, 2014.
3. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67(5):669–683.
4. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010;10(2):67–73.
5. Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. The Botulinum J. 2011;2:49–57.
6. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555–565.
7. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775–1783.
8. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40(3):374–380.
9. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521–1528.
10. Truong DD, Gollomp SM, Jankovic J, et al; Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. J Neural Transm. 2013;120(9):1345–1353.
11. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407–413.
12. Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1–2):116–120.
13. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114.
14. Simpson DM, Blitzer A, Brashear A, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699–1706.
15. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1–2):103–109.
16. Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm. 2013;120(12):1699–1707.
17. Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ. 2012;15(3):419–423.
18. Fernandez HH, Pappert EJ, Comella CL, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3.
19. Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in post-stroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259–265.
20. Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011;43(6):486–492.
21. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study. Acta Neurol Scand. 2010;122(4):295–302.
22. Hesse S, Mach H, Fröhlich S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Clin Rehabil. 2012;26(3):237–245.
23. Simpson DM, Gracies JM, Graham HK, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691–1698.
24. Fernandez HH, Pagan F, Danisi F, et al; XCiDaBLE Study Group. Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3.
25. Fernandez HH, Jankovic J, Holds JB, et al. Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor Other Hyperkinet Mov (N Y). 2014;4:238.
26. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry. 2013;84(9):1014–1019.
27. Fiore P, Santamato A, Ranieri M, et al. Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201. Int J Immunopathol Pharmacol. 2012;25(1 Suppl):57S–62S.
28. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med. 2013;49(4):483–489.
29. Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm. 2013;120(3):469–476.
30. Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm. 2015;122(2):327–333.
31. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–1951.
32. Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014;34(3):233–236.
33. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S; NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303–312.
34. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233–239.
35. Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)). J Neural Transm. 2014;121(1):29–31.
36. Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015;47(2):183–186.
37. Chundury RV, Couch SM, Holds JB. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2013;29(3):205–207.
38. Benecke R. Clinical relevance of botulinum toxin immunogenicity. Bio Drugs. 2012;26(2):e1–e9.
39. Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins – a single cohort 4-year follow-up study. BMJ Open. 2012;2(4).
40. Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ. 2014;17(9):618–625.